adalimumab + methotrexate
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Early Rheumatoid Arthritis
Conditions
Early Rheumatoid Arthritis
Trial Timeline
Oct 1, 2010 โ Sep 1, 2012
NCT ID
NCT01185301About adalimumab + methotrexate
adalimumab + methotrexate is a phase 3 stage product being developed by AbbVie for Early Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01185301. Target conditions include Early Rheumatoid Arthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02196701 | Phase 3 | Completed |
| NCT01185301 | Phase 3 | Completed |
| NCT01185288 | Approved | Completed |
| NCT01162421 | Approved | Completed |
| NCT00808509 | Approved | Completed |
| NCT00783510 | Pre-clinical | Completed |
Competing Products
20 competing products in Early Rheumatoid Arthritis